Perspectives in Psychedelic Medicine
As part of the National Public Health Week programming at Northeastern, come join the NU chapter of Students for Sensible Drug Policy as we host our third annual Psychedelic Research panel, co-sponsored by the NU Health Disparities Student Collaborative.
The featured speakers are:
Dr. John Halpern, Harvard Psychiatrist and researcher who has conducted studies on the cognitive effects of peyote and MDMA, and is currently working on development of an LSD analogue for use in the treatment of Cluster Headaches. Dr. Halpern has a private practice at McLean Hospital in Belmont.
Dr. Rick Doblin, the founder and Executive Director of MAPS (Multidisciplinary Association for Psychedelic Studies). MAPS funds clinical trials that are aimed at developing psychedelic drugs and marijuana into prescription medicines. MAPS funded MDMA trials are currently in phase II of the FDA drug development process for use in the treatment of post traumatic stress disorder.
An undergraduate Northeastern student who used the psychedelic drug ibogaine to treat his opiate addiction.
Thursday, April 4, 2013 at 7:00pm
Snell Engineering, 108